NOTE: This video is ONLY available to watch in selected countries and geographies
The prospective, randomised CARESTAR study, which is currently evaluating the management of symptomatic non-stenotic carotid disease (SyNC) using the CARESTO heal stent (Acandis), has the potential to inform more advanced, personalised treatment paradigms in these patients. That is according to the study’s coordinating investigators, Mayank Goyal (Calgary, Canada) and Hannes Nordmeyer (Solingen, Germany).
Speaking to NeuroNews at the 2025 European Society of Minimally Invasive Neurological Therapy (ESMINT) annual congress (3–5 September, Marseille, France), Goyal—a leading expert in carotid plaque morphology—outlines the current guidelines on SyNC as well as how these patients are diagnosed and defined today, while Nordmeyer—the first clinician to use the CARESTO heal stent in SyNC—focuses on the characteristics that make the device so well-suited to this disease, in addition to highlighting the main goals of the CARESTAR study.
This video is sponsored by Acandis.
